Office of Health Economics -
Health technology assessment approaches in the UK (as well as some other countries) limit themselves to evaluating health benefits that accrue to treated individuals and resource use within the healthcare system. As a result, vaccines and other technologies that generate broader benefits – such as maintaining healthcare capacity or labour productivity – may be undervalued and underused. This report on the broader value of vaccines (commissioned by the ABPI Vaccines Group) sets out actionable short and long term recommendations on how to drive change towards recognising and rewarding the broader value of vaccines in the UK.